



lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

## Submission Confirmation

---

**International Journal of Surgery Case Reports** <em@editorialmanager.com>  
Reply-To: International Journal of Surgery Case Reports <ijscasereports@elsevier.com>  
To: lukman hakim <lukman-h@fk.unair.ac.id>

Sun, Jan 16, 2022 at 8:50 PM

Dear lukman,

We have received your article "Adjuvant Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia" for consideration for publication in International Journal of Surgery Case Reports.

Your manuscript will be given a reference number once an editor has been assigned.

To track the status of your paper, please do the following:

1. Go to this URL: <https://www.editorialmanager.com/ijscasereports/>
2. Your username is: lukmanhakim  
If you need to retrieve password details, please go to: <https://www.editorialmanager.com/ijscasereports/l.asp?i=598231&l=0KDBXQ6E>.
3. Click [Author Login]  
This takes you to the Author Main Menu.
4. Click [Submissions Being Processed]

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager  
International Journal of Surgery Case Reports

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijscasereports/login.asp?a=r>). Please contact the publication office if you have any questions.



lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

**A manuscript number has been assigned: IJSCASEREPORTS-D-22-00072**

---

**International Journal of Surgery Case Reports** <em@editorialmanager.com>

Mon, Jan 17, 2022 at 3:27 AM

Reply-To: International Journal of Surgery Case Reports &lt;ijscasereports@elsevier.com&gt;

To: lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

Ms. Ref. No.: IJSCASEREPORTS-D-22-00072

Title: Adjuvant Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia  
International Journal of Surgery Case Reports

Dear Dr. hakim,

Your submission "Adjuvant Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia" has been assigned manuscript number IJSCASEREPORTS-D-22-00072.

To track the status of your paper, please do the following:

1. Go to this URL: <https://www.editorialmanager.com/ijscasereports/>
2. Enter your login details
3. Click [Author Login]  
This takes you to the Author Main Menu.
4. Click [Submissions Being Processed]

Thank you for submitting your work to International Journal of Surgery Case Reports.

Kind regards,

Maliha Agha  
Assistant Managing and Executive Editor  
International Journal of Surgery Case Reports

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijscasereports/login.asp?a=r>). Please contact the publication office if you have any questions.



lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

## Your submission

---

**International Journal of Surgery Case Reports** <em@editorialmanager.com>

Tue, Feb 1, 2022 at 7:32 PM

Reply-To: International Journal of Surgery Case Reports &lt;ijscasereports@elsevier.com&gt;

To: lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

Ms. Ref. No.: IJSCASEREPORTS-D-22-00072

Title: Adjuvant Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia  
International Journal of Surgery Case Reports

Dear Dr. hakim,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript. If you are prepared to undertake the work required, we would be pleased to reconsider our decision.

For your guidance, reviewers' comments are appended below.

If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is being raised when you submit the revised manuscript.

To submit a revision, please go to <https://www.editorialmanager.com/ijscasereports/> and login as an Author.

Your username is: lukmanhakim

<https://www.editorialmanager.com/ijscasereports/l.asp?i=606291&l=2UL8S7UH>

On your Main Menu page is a folder entitled "Submissions Needing Revision". You will find your submission record there.

Finally, we would appreciate if you could submit your revised paper by Feb 11, 2022.

Yours sincerely,

The Editors

International Journal of Surgery Case Reports

Have you considered publishing a protocol for your next study? You can now publish your study protocol with IJS Protocols, our pioneering new journal for surgical protocols, visit <http://www.ijsprotocols.com> for more details.

Reviewers' comments:

Reviewer #3: The authors have presented a rare case of synovio sarcoma of the kidney. They have suggested the use of adjuvant chemotherapy for benefit to the patient. The discussion is also good. However, there are some concerns.

1. There are some grammatical corrections, which require to be addressed. The suggestions are given in the proof returned.
2. The references are wrongly detailed with initials before the names. They should all be corrected in Vancouver style with initials after the last name.
3. The authors may discuss why neo adjuvant chemotherapy was not considered in the first phase as the tumour appeared to be very large. second, why adjuvant chemotherapy was not considered after the histopathology report identified synovio sarcoma.

Assistant Managing Editor

Please can you make the following changes/checks:

1. Please ensure your case report is compliant with the SCARE Guidelines 2020: <http://www.scareguideline.com> and

submit a completed SCARE 2020 checklist.

Please pay particular attention to the following criteria which are often missed:

- Who performed the procedure? (item 9d)
- patient perspective (item 12)
- Drug history, family history including any relevant genetic information, and psychosocial history (item 5d)
- Where relevant - intervention adherence and tolerability (item 10c)
- Post-intervention considerations (item 9f)

2. Please also ensure you state that the work has been reported in line with the SCARE 2020 criteria:

Agha RA, Franchi T, Sohrabi C, Mathew G, for the SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines, International Journal of Surgery 2020;84:226-230.

3. Please cite the SCARE 2020 paper above in your text in the methods section and the add the reference to your references section.

4. Please ensure you submit a structured abstract with sub-headings as follows:  
Introduction and importance, Case presentation, clinical Discussion, Conclusion

5. Can you also please ensure you go through the entire manuscript and check the spelling, grammar and syntax and ensure the language is concise. If you need our author support services, you can access them here:  
<https://www.ijspg.com/services/author-support>

6. Please be very clear about what this adds to the existing literature and clearly detail learning points.

7. Please ensure you submit your work with a Research Registry unique identifying number (UIN) if its first in man i.e. the first time a new device or surgical technique is performed: [www.researchregistry.com](http://www.researchregistry.com) – it can't progress without being registered. Please ensure you also state your registration UIN in your methods section and reference it including a hyperlink to it if registration is appropriate.

8. If you haven't already, please include your "highlights" which are 3-5 bullet points summarising the novel aspects and/or learning points (maximum 85 characters, including spaces, per bullet point).

9. The consent statement in the author form is not suitable. We need a statement like this:

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Please see consent section in instructions to authors for further information.

10. Please ensure any images/figures/photos are suitably anonymised with no patient information or means of identifying the patient.

11. Please add a Guarantor on the Author form, if you haven't already.

The guarantor is that individual who accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

12. Please add the following statement above references:

Provenance and peer review  
Not commissioned, externally peer-reviewed

13. Above references, please state the following headings with your response (if something doesn't apply, say N/a or none or none declared):

- conflicts of interest
- sources of funding
- ethical approval
- consent
- author contribution
- research registration (for case reports detailing a new surgical technique or new equipment/technology)
- Guarantor

14. Author Form

Please ensure that you have completed and uploaded the correct author form for IJS Case Reports:

[https://www.elsevier.com/\\_\\_data/promis\\_misc/2020\\_IJSCR\\_Author\\_Disclosure\\_Form.docx](https://www.elsevier.com/__data/promis_misc/2020_IJSCR_Author_Disclosure_Form.docx).

Please also make sure that you complete each section of the form.

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijscasereports/login.asp?a=r>). Please contact the publication office if you have any questions.



lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

## Your Submission

---

**International Journal of Surgery Case Reports** <em@editorialmanager.com>  
Reply-To: International Journal of Surgery Case Reports <ijscasereports@elsevier.com>  
To: Lukman Hakim <lukman-h@fk.unair.ac.id>

Mon, Feb 28, 2022 at 1:55 AM

Ms. Ref. No.: IJSCASEREPORTS-D-22-00072R2  
Title: Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia  
International Journal of Surgery Case Reports

Dear Dr. Hakim,

I am pleased to inform you that your paper "Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia" has been accepted for publication in International Journal of Surgery Case Reports.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders.

In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal: <http://www.elsevier.com/journals/International-Journal-of-Surgery-Case-Reports/2210-2612/open-access-options>

We appreciate and value your contribution to International Journal of Surgery Case Reports. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

The Editors  
International Journal of Surgery Case Reports

Comments from the editors and reviewers:

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijscasereports/login.asp?a=r>). Please contact the publication office if you have any questions.

---

**IMPORTANT – Track your article [IJSCR\_106895]**

---

**Elsevier - Article Status** <Article\_Status@elsevier.com>  
To: lukman-h@fk.unair.ac.id

Mon, Feb 28, 2022 at 4:05 AM

**ELSEVIER**

## Track your article!

Dear Dr. Hakim,

Your article *Doxorubicin And Ifosfamide For Recurrent Renal Synovial Sarcoma: The First Case Report in Indonesia* will be published in International Journal of Surgery Case Reports.

To track the status of your article throughout the publication process, please use our article tracking service:

<https://authors.elsevier.com/tracking/article/details.do?aid=106895&jid=IJSCR&surname=Hakim>

For help with article tracking go to [Elsevier Support](#).

We are committed to publishing your article as quickly as possible. We will therefore send you an alert of each next step in the production process where your involvement is required.

Once the expected dispatch date of your proofs is available, you will be automatically alerted by e-mail.

Yours sincerely,

Elsevier Researcher Support

**Have questions or need assistance?**


Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](#) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add [Article\\_Status@elsevier.com](mailto:Article_Status@elsevier.com) to your address book or safe senders list.





lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

**IMPORTANT PLEASE TAKE ACTION, Production has begun on your article [IJSCR\_106895] in International Journal of Surgery Case Reports**

---

jp.binondo@elsevier.com &lt;jp.binondo@elsevier.com&gt;

Tue, Mar 1, 2022 at 12:54 PM

To: lukman-h@fk.unair.ac.id

-----  
Our reference: IJSCR 106895

Article reference: IJSCR\_IJSCASEREPORTS-D-22-00072

Article title: Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia

To be published in: International Journal of Surgery Case Reports

-----  
Dear Dr. Hakim,

Congratulations on your accepted paper! Thank you for choosing to publish in International Journal of Surgery Case Reports. Please read this e-mail carefully as it contains important information.

**FINALIZE PUBLISHING YOUR ARTICLE:**

We work hard to publish our authors' articles online as quickly as possible, so we're happy to report that processing of your manuscript has already begun. To ensure that we publish your article in accordance with your wishes, please now complete these forms

<http://authors.elsevier.com/authorforms/IJSCR106895/16c74322435303b54df8c81ce494bc60>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser. You should log in with your Elsevier Profile credentials, which you may have already created when submitting your article.

**CHECK YOUR CONTACT DETAILS:**

Please check that your details listed below are correct so we can contact you if needed:

Dr. Lukman Hakim

Department of Urology, Faculty of Medicine, Universitas Airlangga - Universitas Airlangga Teaching Hospital, Surabaya, East Java, Indonesia

Urology

Airlangga University Faculty of Medicine: Universitas Airlangga Fakultas Kedokteran Indonesia

Phone: not available

Fax: not available

E-mail: [lukman-h@fk.unair.ac.id](mailto:lukman-h@fk.unair.ac.id)**YOUR REFERENCE NUMBER:**

To help us provide you with the best service, please make a note of your article's reference number IJSCR 106895 and quote it in all of your messages to us.

If you wish to find out more about the next steps in the publication process and for further help and / or information please visit our Author hub, link below:

[https://service.elsevier.com/app/answers/detail/a\\_id/34514/c/10532/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/34514/c/10532/supporthub/publishing/)

Thank you for your cooperation.

Kind regards,

Mr Jericjames Paltingca Binondo



Data Administrator  
Elsevier  
E-Mail: [jp.binondo@elsevier.com](mailto:jp.binondo@elsevier.com)

-----  
HAVE QUESTIONS OR NEED ASSISTANCE?

For further assistance, Please feel free to talk to our Researcher support team via 24/7 live chat and e-mail or avail our phone support for 24/7. Please visit our Elsevier support Center where you can search for solutions on a range of topics and find answers to frequently asked questions, Get started here:

<http://service.elsevier.com/app/home/supporthub/publishing>

-----  
Copyright © 2015 Elsevier B.V. | Privacy Policy <http://www.elsevier.com/privacypolicy>  
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084



lukman hakim &lt;lukman-h@fk.unair.ac.id&gt;

---

**Corrections received - [IJSCR\_106895]**

---

**optteam@elsevierproofcentral.com** <optteam@elsevierproofcentral.com>  
To: lukman-h@fk.unair.ac.id

Fri, Mar 4, 2022 at 6:06 PM

This is an automatically generated message. Please do not reply because this mailbox is not monitored.

Dear Dr. Lukman Hakim,

Thank you very much for using the Proof Central application for your article "Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia" in the journal "IJSCR"

All your corrections have been saved in our system. The PDF summary of your corrections, generated from Proof Central, can be downloaded from the following site for your reference:

[https://pcv3-elsevier-live.s3.amazonaws.com/f483b2f9feb84479549d6384d3e54c/IJSCR\\_106895\\_edit\\_report.pdf](https://pcv3-elsevier-live.s3.amazonaws.com/f483b2f9feb84479549d6384d3e54c/IJSCR_106895_edit_report.pdf)

To track the status of your article throughout the publication process, please use our article tracking service:

[http://authors.elsevier.com/TrackPaper.html?trk\\_article=IJSCR106895&trk\\_surname=](http://authors.elsevier.com/TrackPaper.html?trk_article=IJSCR106895&trk_surname=)

For help with article tracking:

[http://support.elsevier.com/app/answers/detail/a\\_id/90](http://support.elsevier.com/app/answers/detail/a_id/90)

Kindly note that now we have received your corrections, your article is considered finalised and further amendments are no longer possible.

For further assistance, please visit our customer support site at <http://support.elsevier.com>. Here you can search for solutions on a range of topics. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

Yours sincerely,  
Elsevier Proof Central team

When you publish in an Elsevier journal your article is widely accessible. All Elsevier journal articles and book chapters are automatically added to Elsevier's SciVerse Science Direct which is used by 16 million researchers. This means that Elsevier helps your research get discovered and ensures that you have the greatest impact with your new article.

[www.sciencedirect.com](http://www.sciencedirect.com)

---

**Publishing Agreement completed for your article [IJSCR\_106895]**

---

**Elsevier - Author Forms** <Article\_Status@elsevier.com>  
To: lukman-h@fk.unair.ac.id

Wed, Mar 9, 2022 at 10:50 PM

# ELSEVIER

Dear Dr. Hakim,

Thank you for completing the Publishing Agreement Form for your article *Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia*. Please find attached a copy of the "Journal Publishing (License) Agreement" which you completed online on March 09, 2022.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference IJSCR\_106895 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: [www.elsevier.com/sharing-articles](http://www.elsevier.com/sharing-articles).

We are committed to publishing your article as quickly as possible.

Kind regards,  
Elsevier Researcher Support


**Have questions or need assistance?**

Please do not reply to this automated message. For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions. You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>  
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add [Article\\_Status@elsevier.com](mailto:Article_Status@elsevier.com) to your address book or safe senders list.



---

 **IJSCR106895.html**  
19K